Hudson Bay Capital Management
BMY.RT

Hudson Bay Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Hudson Bay Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,216,463
Closed -$839K – 1124
2020
Q4 		$839K Sell
1,216,463
-533,055
-30% -$1.14M 0.01% 470
2020
Q3 		$3.94M Sell
1,749,518
-206,289
-11% -$589K 0.06% 270
2020
Q2 		$7M Buy
1,955,807
+112,580
+6% +$406K 0.12% 153
2020
Q1 		$7M Buy
1,843,227
+301,411
+20% +$993K 0.18% 109
2019
Q4 		$4.64M Buy
+1,541,816
New +$4.01M 0.1% 181

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Hudson Bay Capital Management's BMY.RT Position: Q1 2021 in Review

Hudson Bay Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,216,463 shares — an estimated $839K sold.

Hudson Bay Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $7M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Hudson Bay Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,216,463 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $839K.
  • Hudson Bay Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Hudson Bay Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $7M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Hudson Bay Capital Management's 13F filing for Q1 2021, filed 14 May 2021.